AU2022239950B2 - Pyrazolopyridine derivatives and uses thereof - Google Patents

Pyrazolopyridine derivatives and uses thereof Download PDF

Info

Publication number
AU2022239950B2
AU2022239950B2 AU2022239950A AU2022239950A AU2022239950B2 AU 2022239950 B2 AU2022239950 B2 AU 2022239950B2 AU 2022239950 A AU2022239950 A AU 2022239950A AU 2022239950 A AU2022239950 A AU 2022239950A AU 2022239950 B2 AU2022239950 B2 AU 2022239950B2
Authority
AU
Australia
Prior art keywords
methyl
pyrazolo
pyridin
dione
dihydropyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022239950A
Other languages
English (en)
Other versions
AU2022239950A1 (en
Inventor
Simone BONAZZI
Artiom CERNIJENKO
Jennifer Stroka Cobb
Natalie Alysia DALES
Janetta DEWHURST
Matthew James HESSE
Rama Jain
John Ryan Kerrigan
Hasnain Ahmed Malik
James R. MANNING
Gary O'brien
Andrew W. Patterson
Noel Marie-France THOMSEN
Pamela YF TING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2022239950A1 publication Critical patent/AU2022239950A1/en
Application granted granted Critical
Publication of AU2022239950B2 publication Critical patent/AU2022239950B2/en
Priority to AU2024278210A priority Critical patent/AU2024278210B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022239950A 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof Active AU2022239950B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024278210A AU2024278210B2 (en) 2021-03-15 2024-12-09 Pyrazolopyridine derivatives and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161139P 2021-03-15 2021-03-15
US63/161,139 2021-03-15
US202163164130P 2021-03-22 2021-03-22
US63/164,130 2021-03-22
PCT/IB2022/052281 WO2022195454A1 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024278210A Division AU2024278210B2 (en) 2021-03-15 2024-12-09 Pyrazolopyridine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2022239950A1 AU2022239950A1 (en) 2023-08-31
AU2022239950B2 true AU2022239950B2 (en) 2024-09-12

Family

ID=80819999

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022239950A Active AU2022239950B2 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof
AU2024278210A Active AU2024278210B2 (en) 2021-03-15 2024-12-09 Pyrazolopyridine derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024278210A Active AU2024278210B2 (en) 2021-03-15 2024-12-09 Pyrazolopyridine derivatives and uses thereof

Country Status (19)

Country Link
US (4) US11787785B2 (https=)
EP (1) EP4308562A1 (https=)
JP (2) JP7659648B2 (https=)
KR (1) KR102902295B1 (https=)
AU (2) AU2022239950B2 (https=)
CA (1) CA3208951A1 (https=)
CL (1) CL2023002726A1 (https=)
CO (1) CO2023013486A2 (https=)
CR (1) CR20230486A (https=)
DO (1) DOP2023000188A (https=)
EC (1) ECSP23076800A (https=)
IL (1) IL305931A (https=)
JO (1) JOP20230218A1 (https=)
MX (1) MX2023010827A (https=)
PE (1) PE20242203A1 (https=)
PY (1) PY2217419A (https=)
UY (1) UY39671A (https=)
WO (1) WO2022195454A1 (https=)
ZA (1) ZA202307290B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PY2217419A (es) 2021-03-15 2022-09-27 Novartis Ag Derivados de pirazolopiridina y sus usos
WO2022195355A1 (en) * 2021-03-15 2022-09-22 Novartis Ag Benzisoxazole derivatives and uses thereof
EP4612128A4 (en) 2022-11-04 2025-09-10 Bristol Myers Squibb Co COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
KR20060109979A (ko) 2003-12-02 2006-10-23 셀진 코포레이션 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
PL3202460T3 (pl) * 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2020009513A (ja) * 2018-07-10 2020-01-16 キオクシア株式会社 メモリシステム
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220138399A (ko) 2020-02-04 2022-10-12 스팅레이 테라퓨릭스, 인크. 엑토뉴클레오티드 피로포스파타제/포스포디에스테라제 1(enpp1)의 억제제 및 이의 사용 방법
US20230089530A1 (en) 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
PY2217419A (es) 2021-03-15 2022-09-27 Novartis Ag Derivados de pirazolopiridina y sus usos

Also Published As

Publication number Publication date
JOP20230218A1 (ar) 2023-09-14
CO2023013486A2 (es) 2023-11-10
JP7659648B2 (ja) 2025-04-09
AU2024278210A1 (en) 2025-01-02
AU2024278210B2 (en) 2026-03-26
JP2024509981A (ja) 2024-03-05
MX2023010827A (es) 2023-09-28
CA3208951A1 (en) 2022-09-22
BR112023018542A2 (pt) 2023-10-10
JP2025106341A (ja) 2025-07-15
AU2022239950A1 (en) 2023-08-31
ZA202307290B (en) 2024-09-25
NZ802195A (en) 2025-10-31
US20230108325A1 (en) 2023-04-06
IL305931A (en) 2023-11-01
US20250002479A1 (en) 2025-01-02
US12252482B2 (en) 2025-03-18
US11787785B2 (en) 2023-10-17
ECSP23076800A (es) 2023-11-30
UY39671A (es) 2022-10-31
TW202304900A (zh) 2023-02-01
PE20242203A1 (es) 2024-11-19
WO2022195454A1 (en) 2022-09-22
US20240158374A1 (en) 2024-05-16
PY2217419A (es) 2022-09-27
US20250282762A1 (en) 2025-09-11
US12172984B2 (en) 2024-12-24
EP4308562A1 (en) 2024-01-24
CR20230486A (es) 2024-01-25
KR102902295B1 (ko) 2025-12-23
KR20230156766A (ko) 2023-11-14
CL2023002726A1 (es) 2024-04-01
DOP2023000188A (es) 2023-11-15

Similar Documents

Publication Publication Date Title
ES2980575T3 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
AU2022239950B2 (en) Pyrazolopyridine derivatives and uses thereof
AU2014261894A1 (en) Biheteroaryl compounds and uses thereof
KR20240013812A (ko) 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 의학적 용도
JP2023535096A (ja) キナーゼ阻害活性を有する化合物
US20250276964A1 (en) Benzisoxazole Derivatives and Uses thereof
CN116802182A (zh) 吡唑并吡啶衍生物及其用途
CN116940571A (zh) 苯并异噁唑衍生物及其用途
EA051403B1 (ru) Производные пиразолопиридина и пути их применения
BR112023018542B1 (pt) Derivados de pirazolopiridina, e composição e combinação farmacêuticas
BR122025004894A2 (pt) Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)